News >

Lead KATE2 Author Suggests Atezolizumab Benefits HER2+ Breast Cancer Subgroup

Jessica Hergert
Published: Tuesday, Oct 08, 2019

Dr. Leisha A. Emens, a professor of medicine in hematology/oncology, co-leader of the Hillman Cancer Immunology Program, director of translational immunotherapy for the Women's Cancer Research Center at UPMC Hillman Cancer Center

Leisha A. Emens, MD, PhD

Updated results of the randomized, phase II KATE2 trial suggest an overall survival (OS) benefit with atezolizumab plus ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone for patients with HER2-positive breast cancer who have PD-L1 expression on immune cells, reported Leisha A. Emens, MD, PhD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication